hVIVO plc Successful RSV Challenge Study in Older Adults
06 Agosto 2019 - 3:01AM
RNS Non-Regulatory
TIDMHVO
hVIVO plc
06 August 2019
RNS REACH
hVIVO plc
("hVIVO" or the "Company")
hVIVO successfully completes RSV challenge study in Older
Adults
- Represents a new model available to customers as part of
hVIVO's clinical trial services offering -
- Respiratory syncytial virus (RSV) human challenge study
conducted by hVIVO in adults aged 60-75 delivers positive
results
- Study demonstrated that an RSV challenge study can be
performed safely in this age group
- Broadens hVIVO's commercial offering in RSV beyond its already
established RSV model in the younger population
- Utilisation of the Older Adult model targets population
associated with significant unmet need in RSV
London, UK - 6 August 2019: hVIVO plc (AIM: HVO), an industry
leading clinical development services business pioneering human
disease models based upon viral challenge, announces the successful
completion of an RSV human challenge study conducted in older
adults, aged 60-75 years. The study was conducted at hVIVO's
specialist clinical facility in London.
The study demonstrated that an RSV challenge model can be
conducted safely in a population of 60-75 years of age.
The study, which extends hVIVO's commercial provision beyond the
established RSV human challenge model in 18-60 year olds, comprised
volunteers who were residential in hVIVO's state of the art human
challenge clinical unit for a period of approximately 2 weeks after
being inoculated with hVIVO's GMP-manufactured RSV Memphis 37
Challenge virus strain. Each volunteer was closely monitored 24
hours a day with data concerning safety, infection rates, virology
and symptoms collected before being safely discharged and followed
up for 28 days post discharge.
The hVIVO RSV Older Adult challenge model in 60-75 year olds,
was specifically designed to provide the pharmaceutical industry
with an early clinical development proof of concept platform to
safely evaluate novel treatments/vaccines in one of the populations
with the greatest unmet medical need.
Dr Trevor Phillips, Executive Chairman, commented:
"We are pleased to announce results from this study in an older
adult population and broadening hVIVO's commercial offering in RSV
beyond its already established model in the younger population that
is currently the only such RSV model commercially available. These
positive results mean we are now able to offer existing and new
customers a model that targets a population that is particularly
vulnerable to RSV and for use in vaccine or antiviral product
development.
The Company's contract pipeline is experiencing a strong demand
for RSV challenge study services and we anticipate this demand will
continue reflective of the unmet medical need that companies are
addressing."
For further information please contact:
hVIVO plc
Trevor Phillips (Executive Chairman) +44 207 756 1300
Fleur Wood (EVP, Investor Relations & Communications)
Numis Securities Limited +44 207 260 1000
Freddie Barnfield / Huw Jeremy (Nominated Adviser)
James Black (Corporate Broking)
FTI Consulting
Simon Conway / Victoria Foster Mitchell +44 203 727 1000
Notes to Editors:
hVIVO is pioneering a human-based clinical trial platform to
accelerate drug and vaccine development in respiratory and
infectious diseases. Leveraging human disease models in HRV, RSV,
Flu Asthma and COPD, the hVIVO platform captures disease in motion,
illuminating the entire disease life cycle from healthy to sick and
back to health. Based in the UK, market leader hVIVO has conducted
more than 50 clinical studies and inoculated over 2500
volunteers.
Forward-looking statements
This announcement includes statements that are, or may be deemed
to be, forward-looking statements. These forward-looking statements
can be identified by the use of forward-looking terminology,
including the terms anticipates, believes, estimates, expects,
intends, may, plans, projects, should or will, or, in each case,
their negative or other variations or comparable terminology, or by
discussions of strategy, plans, objectives, goals, future events or
intentions. These forward-looking statements include all matters
that are not historical facts. Any forward-looking statements in
this announcement reflect the Group's (or, as the case may be, the
hVIVO directors') current view with respect to future events and
are subject to risks relating to future events and other risks,
uncertainties and assumptions relating to the Group's operations,
results of operations and growth strategy. Investors should
specifically consider the factors identified in this announcement
which could cause actual results to differ before making an
investment decision.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABUGDIXSGBGCU
(END) Dow Jones Newswires
August 06, 2019 02:01 ET (06:01 GMT)
Hvivo (LSE:HVO)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Hvivo (LSE:HVO)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024